Literature DB >> 3490912

Non-human primate (baboon) anti-gross cystic disease fluid protein-15 antibody infusion in four women with metastatic breast carcinoma.

A Estabrook, S J Kister, M A Hardy, L Grossbard, M W Oster, S Davis, G Mazoujian, D E Haagensen.   

Abstract

Four women with metastatic breast carcinoma and elevated plasma levels of human breast gross cystic disease fluid protein of 15,000 dalton monomer size (GCDFP-15) were treated IV with non-human primate (baboon) anti-GCDFP-15 antibody. Three patients were given a single IV infusion of antibody, while the fourth patient received four sequential IV infusions. Antibody dosage patients, after antibody infusion the plasma level of GCDFP-15 decreased to 0 ng/ml and remained there as long as "free" circulating anti-GCDFP-15 antibody was present. The plasma half-life of the antibody ranged between 1 and 40 h and the duration of detectable free antibody ranged from 6 to 240 h. No toxicity was observed for the dosage range of antibody tested. No anti-baboon antibody response was detected. In the patient who received four sequential infusions of antibody partial regression of subcutaneous metastatic nodules occurred. The other three patients showed no clinically detectable changes from the antibody infusion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490912     DOI: 10.1007/BF00199821

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Buffer-exchange column for rapid separation of carcinoembryonic antigen from perchloric acid.

Authors:  D E Haagensen; R L Easterday; C A Stolle; S A Wells
Journal:  Clin Chem       Date:  1978-01       Impact factor: 8.327

2.  Discussion paper: cross-reactivity of primate immunoglobulins.

Authors:  J Shuster; N L Warner; H H Fudenberg
Journal:  Ann N Y Acad Sci       Date:  1969-07-03       Impact factor: 5.691

3.  Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features.

Authors:  G Mazoujian; G S Pinkus; S Davis; D E Haagensen
Journal:  Am J Pathol       Date:  1983-02       Impact factor: 4.307

4.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

Authors:  R A Miller; D G Maloney; R Warnke; R Levy
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

5.  Breast gross cystic disease fluid analysis. I. Isolation and radioimmunoassay for a major component protein.

Authors:  D E Haagensen; G Mazoujian; W G Dilley; C E Pedersen; S J Kister; S A Wells
Journal:  J Natl Cancer Inst       Date:  1979-02       Impact factor: 13.506

6.  Pilot trial of murine monoclonal antibodies in patients with advanced melanoma.

Authors:  G E Goodman; P Beaumier; I Hellström; B Fernyhough; K E Hellström
Journal:  J Clin Oncol       Date:  1985-03       Impact factor: 44.544

7.  Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours.

Authors:  H F Sears; B Atkinson; J Mattis; C Ernst; D Herlyn; Z Steplewski; P Häyry; H Koprowski
Journal:  Lancet       Date:  1982-04-03       Impact factor: 79.321

8.  Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma.

Authors:  D E Haagensen; S J Kister; J Panick; J Giannola; H J Hansen; S A Wells
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

9.  Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

Authors:  A N Houghton; D Mintzer; C Cordon-Cardo; S Welt; B Fliegel; S Vadhan; E Carswell; M R Melamed; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

10.  Immunologic control of the ascites form of murine adenocarcinoma 755. III. Efficacy of serum therapy is controlled by a single genetic locus.

Authors:  G J Roloson; D E Haagensen; C A Chambers; D P Bolognesi
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

View more
  2 in total

1.  Hepatic clearance and metabolism in the rat of a human breast cancer associated glycoprotein (GCDFP-15).

Authors:  C A Toth; D E Haagensen; S Davis; N Zamcheck; P Thomas
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

2.  Non-human primate (baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma. A phase I study.

Authors:  M S Huberman; J J Lokich; T Hill; A Kaldany; A Kassis; T Price; C Moore; S Davis; P Kasulis; A P Monaco
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.